30 results about "MUC1" patented technology

MUC1 binding molecules are provided, including MUC1 single domain antibodies that specifically bind to the MUC1 extracellular region. The invention further relates to an anti-MUC1 single-domain antibody chimeric antigen receptor and application thereof, and particularly provides the chimeric antigen receptor, and an antigen binding domain of the chimeric antigen receptor comprises an MUC1 binding molecule containing the anti-MUC1 single-domain antibody. The immune cell containing the chimeric antigen receptor has a relatively high cell killing effect.

This invention relates to an IL5 / Bi2MoO6 / MXene photoactive composite material, a low-background photoelectrochemical aptamer sensor, its preparation method, and its applications. The sensor is constructed by sequentially modifying chitosan, glutaraldehyde, complementary DNA strands, and a gold nanoparticle-labeled aptamer. A fixed capture probe and APT-Au synergistically achieve dual signal quenching, constructing an extremely low detection baseline. When the target analyte MUC1 is present, its specific binding to the aptamer causes APT-Au to detach, dissolving the dual quenching and significantly restoring the photocurrent, thereby achieving quantitative detection. This invention solves the problems of low efficiency, heterojunction instability, and high baseline in single quenching modes of existing photoelectric materials, achieving highly sensitive, highly specific, rapid, and low-cost detection of the breast cancer biomarker MUC1 in human serum samples, providing a novel, industrially feasible technical solution for large-scale early screening of breast cancer.

Provided are a Surface-Enhanced Raman Scattering (SERS) biosensor based on a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) / Cas13a system and an application thereof, belonging to the field of spectroscopy detection. The SERS biosensor includes an SERS sensor chip, a first reagent, a second reagent, a third reagent, and a fourth reagent. The SERS sensor chip is a silver nanorod array substrate with hairpin Deoxyribonucleic Acid (DNA) single-stranded H1 and blocking molecule 6-mercaptoethanol modified on the surface. The first reagent is a SERS probe and buffer of the probe. The second reagent is hairpin nucleic acid aptamer strand MUC1-apt aqueous solution. The third reagent is the CRISPR / Cas13a system and buffer of the system. The fourth reagent is hairpin DNA single-stranded H2 aqueous solution. The above reagents are mixed with the gastric cancer exosomes to be detected and then dripped on a surface of the SERS sensor chip.

This invention discloses a composite nanozyme and a kit for simultaneous recognition of multiple exosomes. The kit includes an aptamer / composite nanozyme solution, exosome standards, TMB substrate solution, H2O2 solution, and 96-well plate enzyme labeling strips. This invention innovatively utilizes Ti3C2T... x A nanozyme (MX-MnNF) formed by combining MXene nanosheets and MnO2 nanoflowers was constructed, and a colorimetric sensor array was built by modifying it with three aptamers: EpCAM, MUC1, and HER2. Based on the peroxidase-like activity of the nanozyme, it can catalyze the TMB-H2O2 reaction to produce color changes, enabling the simultaneous recognition of multiple exosomes. This method can complete the detection within 10 minutes, with a detection sensitivity of up to 10 particles / mL and an accuracy of up to 95% for clinical samples. It has the advantages of simple operation, rapid detection, and high sensitivity, providing a new technical means for tumor liquid biopsy.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The application belongs to the technical field of biotechnology, and discloses a humanized anti-human MUC1 monoclonal antibody and application thereof, the antibody is humanized by CDR grafting technology, three complementarity determining regions of a light chain variable region and three complementarity determining regions of a heavy chain variable region are retained, an amino acid sequence of the light chain variable region is shown in SEQ ID NO. 11, and a corresponding base sequence is shown in SEQ ID NO. 12; an amino acid sequence of the heavy chain variable region is shown in SEQ ID NO. 13, and a corresponding base sequence is shown in SEQ ID NO. 14. The humanized anti-human MUC1 monoclonal antibody can be specifically combined with MUC1 positive tumor cells, and can kill tumor cells through ADCC and CDC effects; can be used for preparing an anti-tumor drug, and the drug forms include a monoclonal antibody, an ADC, a CAR-T cell preparation and BiTEs, and provides an effective targeting tool for immunotherapy of MUC1 overexpression related tumors.

The application provides a multi-specific antibody monomer having a light chain (LC) and a heavy chain (HC), each having a N-terminal and a C-terminal, comprising, a first scFv domain having a binding affinity to a tumor-associated antigen (TAA) at the N-terminal of the HC (Position 1, or P1), a Fab domain having a binding affinity to CD3, and a second scFv domain having a binding affinity to PD-L1 at the C-terminal of the LC (Position 5, or P5) or the N-terminal of the LC (Position 6, or P6). In some embodiments, the TAA comprises EGFR, HER3, DLL3, HER2, GPC3, HLA-G, uPAR, Nectin4, Fra, Tissue Factor, B7-H4, VEGFR2, B7-H3, Muc16, CEACAM6, Claudin6, CLDN18.2, LGR5, GCC, CD20, CD19, Integrin β6, Muc1, CDH6, FAP, CAIX, Integrin β4, CDH17, Lewis B / Y, GPRC5D, CEACAM5, ROR1, or EGFR vIII.

The invention relates to the field of immunotherapy, in particular to an engineered antigen presenting cell which contains a coding sequence of a multispecific nano antibody. And / or can express and / or secrete a multispecific nano antibody; a tumor-associated antigen is loaded on the carrier, and the tumor-associated antigen is selected from one or more of the following components: P53, Survivin, MUC1, hTERT or KRAS. The antigen presenting cell disclosed by the invention can activate immature T cells and effectively stimulate the effector function of the activated T cells on cancers.

A pharmaceutical composition comprising an antibody-drug conjugate that specifically binds to EGFR and MUC1, and the use thereof in the preparation of a drug used for preventing or treating diseases.

The application discloses a kind of MUC1-CAR-T cells of co-expression BTLA / IL-18R chimeric receptor and preparation method and application thereof, belong to the field of biological medicine technology.The MUC1-CAR-T cell includes BTLA / IL-18R chimeric receptor and MUC1-CAR structure;The present application uses MUC1 as the targeting molecule of CAR-T cell treatment, the extracellular segment of BTLA is connected with the transmembrane region and intracellular section region of IL-18 receptor, and designs co-expression BTLA / IL-18R chimeric receptor.Experiment verifies and finds that BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cell, can better inhibit the growth of tumor, provides a new immunotherapy strategy for the treatment of pancreatic cancer.

The invention relates to polypeptide of a targeted tumor marker MUC1 and application of the polypeptide, and belongs to the technical field of nano medicine and biological materials. The sequence general formula of the polypeptide from the N terminal to the C terminal is X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13, x1, X2 and X3 are hydrophilic amino acids, X4-X12 are combinations of leucine, glutamine, isoleucine, threonine and lysine, and X13 is a hydrophobic amino acid. The polypeptide not only can be combined with a target spot with high affinity, but also can be self-assembled into a zigzag nanoflower, so that recognition residues of the polypeptide are functionally arranged on the surface of the nanoflower. The serrated polypeptide nanoflower can be used as a therapeutic drug in the aspect of tumor treatment, and can also be used as a delivery carrier.

The application provides an antigen epitope polypeptide and a paralichthys ovatus mucin Muc1 specific antibody prepared by the antigen epitope, a B cell epitope from the paralichthys ovatus Muc1 protein is identified through antigen epitope screening, and the amino acid sequence is SEQ ID NO:1. After the epitope is coupled with a KLH carrier protein, a New Zealand white rabbit is immunized, and a rabbit anti-paralichthys ovatus Muc1 polyclonal antibody is successfully prepared. The antibody can specifically recognize the Muc1 protein in paralichthys ovatus mucosa tissue and positive mucous cells, and provides an important detection tool for studying the function mechanism of mucous cells in fish mucosal immunity.

The invention relates to the technical field of biological detection, and discloses a saliva exosome detection kit for non-invasive auxiliary screening of Alzheimer's disease and a preparation method of the saliva exosome detection kit. The specific exosome enrichment system composed of the anti-L1CAM / CD63 double antibody coated capture plate and the anti-MUC1 / KRT19Fab fragment blocking agent is constructed for the first time, about 85% of oral cavity source exosomes can be effectively removed, and the capture purity of neuron source exosomes is remarkably improved; the special saliva preserving fluid containing DTT and a specific enzyme inhibitor is developed, the technical bottlenecks that saliva RNA is easy to degrade and a sample is uneven in viscosity are overcome, and the room temperature stability is prolonged to 8 hours; an RT-qPCR detection system taking saliva exosome miRNA-135a as a core and taking internal reference miRNA-16-5p standardization is established, and clinical sample verification shows that the kit can effectively distinguish the Alzheimer's disease patient from a healthy control, shows excellent inter-group distinguishing ability, and provides a stable, efficient, reliable and complete technical scheme for solving the problem of AD non-invasive early screening.

The present disclosure is directed to antibodies, e.g., monoclonal antibodies, bispecific antibodies and bispecific activatable antibodies that bind MUC1 and / or CD3, and uses of such antibodies, in particular use thereof in the treatment of diseases, e.g., cancers.

Methods, compositions and cells are provided that identify and isolate a population of adult non-embryonic progenitor cells having multilineage potential, physical diameters of about 2 μm to about 8 μm in size or about 4 μm to about 6 μm, and expressing at least one of the stem cell associated genes among Oct-4, KLF-4, Nanog, Sox-2, Rex-1, GDF-3 or Stella. Methods are also provided that identify and isolate populations, which are subsets or subpopulations of progenitor adult stem cells within the population of the adult stem cells which is a heterogeneous population, the methods including contacting the adult stem cells with a ligand specific for at least one of: CD99, tetraspan, ICAM4, full-length MUC1, and truncated MUC1 receptor, in which a presence of a surface protein on the cells that bind to the ligand identifies the population which is the subset of the differentiated progenitor adult stem cells.

The invention discloses an antigen epitope peptide coded by mRNA and fused in phosphatidylinositol anchoring protein and application of the antigen epitope peptide, and belongs to the field of biological medicine. The antigen epitope peptide comprises a MUC1 (1TR)-CD24 molecule and a MUC1 (1TR, 13aa)-CD24 molecule; the MUC1 (1TR)-CD24 molecule comprises an MUC1 signal peptide, an MUC1 extracellular domain containing one MUC1 VNTR sequence, a CD24 polypeptide and a phosphatidylinositol anchoring signal peptide; the MUC1 (1TR, 13aa)-CD24 molecule contains MUC1 signal peptide, MUC1 (1TR, 13aa) sequence, CD24 polypeptide and phosphatidylinositol anchoring signal peptide, the process is simple, the sequence is controllable, CAR-T cell amplification can be efficiently activated, CAR-T cells can be stimulated to secrete anti-tumor cell factors, and the MUC1 (1TR, 13aa)-CD24 molecule has important medical value in preparation of drugs for treating cancers or preventing cancer relapse.

The invention relates to antibody drug conjugates comprising an antibody that specifically binds to tumor-associated Mucin 1 (TA-MUC1) of human epithelial tumor cells, but not to highly glycosylated MUC1 on healthy epithelial cells, wherein the antibody is coupled to a cytotoxic agent selected from the group consisting of a tubulin inhibitor or a topoisomerase inhibitor. The invention furthermore relates to a pharmaceutical composition, comprising such an antibody drug conjugate for use in the treatment of malignant epithelial tumors.

Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.

The invention relates to a multi-target tumor gene vaccine and application thereof, and belongs to the technical field of biotechnology drugs. The invention provides a molecular composition, which comprises hXCL1, FAPalpha, MUC1 and survivin, and the FAPalpha is an amino acid of an extracellular domain 27-760, the MUC1 is an amino acid of an extracellular domain 27-760, and the survivin is an amino acid of an extracellular domain 27-760. MUC1 is 9M of a repetitive fragment containing 9 MUC1 VNTR copies or 33M of a repetitive fragment containing 33 MUC1 VNTR copies, survivin is a spliceosome S8 with seven amino acids removed at the N-end, and meanwhile, P2A peptide is connected with an IL-2 adjuvant to enhance the treatment effect of the vaccine. The vaccine is prepared from the molecular composition for the first time, and good immunogenicity and antitumor activity can be generated. The vaccine provided by the invention can be used for immunizing to generate specific cellular immune response aiming at FAP alpha, MUC1 and survivin.

To obtain a bacterium inhibiting the proliferation of S. aureus and E. coli and participating in the increase of the expression of genes of six factors of CLD1, OCLN, elafin, MUC1, HAS1 and HAS3 relating to the barrier function of vaginal tissues and a preparation, etc., utilizing a culture supernatant or dead cells obtained from the bacterium.SOLUTION: A BG-strain of STBs325 belonging to the species Lactobacillusparagasseri deposited under accession number NITEP - 04114, wherein the culture supernatant inhibits the growth of S. aureus and E. coli and increases the expression of the genes for the six factors CLD1, OCLN, Elafin, MUC1, HAS1, HAS3, which are associated with the barrier function of vaginal tissue. A preparation using the culture supernatant or dead bacterial cells of the bacteria can be used as an agent for suppressing proliferation of Staphylococcus aureus or Escherichia coli and as an agent for improving the barrier function of vaginal tissue.SELECTED DRAWING: Figure 2

An anti-tumor fusion protein can inhibit the growth of MUC1-positive tumor cells, and can inhibit the growth of pancreatic cancer tumor cells. The fusion protein may contain protein MBP and protein MUC1-N. An amino acid sequence of the fusion protein is set forth in SEO ID NO.3. The fusion protein can be used for the prevention and / or treatment of pancreatic cancer.

This document provides methods and materials relating to isolated polypeptides, polypeptide preparations, vaccine preparations (e.g., anti-cancer vaccine preparations), and methods for vaccinating mammals. For example, polypeptides (e.g., CMV, MUC1, HER2, Mesothelin (MESO), TRAG-3, or CALR polypeptides) having the ability to be processed into different polypeptides such that the processed polypeptides as a group are capable of being presented by different MHC molecules present in a particular mammalian population are provided.

The invention relates to the field of immunotherapy, in particular to an engineered antigen presenting cell which contains a coding sequence of a multispecific nano antibody. And / or can express and / or secrete a multispecific nano antibody; the invention discloses a tumor-associated antigen carrier, which is characterized by being loaded with tumor-associated antigens, the tumor-associated antigens are selected from one or more of P53, Survivin and MUC1, and the Survivin is connected with the P53 in series. The antigen presenting cell disclosed by the invention can activate immature T cells and effectively stimulate the effector function of the activated T cells on cancers.

The present application discloses an antibody, or fragment thereof, for the diagnosis, treatment or prevention of cancers wherein the antibody specifically binds to the PSMGFR peptide (SEQ ID NO:2) or a fragment thereof of the peptide.

The present disclosure relates to: an antibody-drug conjugate of an anti-EGFR / MUC1 bispecific antibody; and a use thereof for tumor treatment.

The invention relates to a response type nano-micelle based on PROTAC as well as a preparation method and application of the response type nano-micelle. The nano-micelle is a PROTAC micelle doped with disulfide bonds and formed by self-assembly of MUC1-targeted PROTAC molecules and functional lipid, wherein the PROTAC molecule of the target MUC1 comprises an MUC1 aptamer and a small molecule drug of the target E3 ubiquitin ligase; and the functional lipid comprises disulfide bond connecting lipid and auxiliary lipid. The invention further discloses a preparation method and application of the response type nano-micelle based on PROTAC. The preparation method is simple, the main body material is convenient to obtain, and the biological safety is good; the tumor microenvironment is effectively remodeled, and immune cell infiltration is enhanced; the used materials are novel, the combined treatment effect is enhanced through cascade reaction, and the maximization of the curative effect of the medicine is realized; the coated medicine has a controlled release effect, and the safety, effectiveness and utilization rate of the medicine can be improved.

To obtain a bacterium inhibiting the proliferation of S. aureus and E. coli and participating in the increase of the expression of genes of six factors of CLD1, OCLN, elafin, MUC1, HAS1 and HAS3 relating to the barrier function of vaginal tissues and a preparation, etc., utilizing a culture supernatant or dead cells obtained from the bacterium.SOLUTION: A BG-strain of DL427 belonging to the species Lactobacillusparagasseri deposited under accession number NITEP - 04115, wherein the culture supernatant inhibits the growth of S. aureus and E. coli and increases the expression of the genes for the six factors CLD1, OCLN, Elafin, MUC1, HAS1, HAS3, which are associated with the barrier function of vaginal tissue. A preparation using the culture supernatant or dead bacterial cells of the bacteria can be used as an agent for suppressing proliferation of Staphylococcus aureus or Escherichia coli and as an agent for improving the barrier function of vaginal tissue.SELECTED DRAWING: Figure 2

The invention belongs to the technical field of medical biological research, and particularly relates to construction and evaluation of a chronic obstructive pulmonary epithelial cell senescence model. A method for constructing a chronic obstructive pulmonary epithelial cell senescence model comprises the following steps: exposing tobacco smoke after 6-8 weeks of Muc1 gene whole-body knockout mice and / or exposing tobacco smoke after 6-8 weeks of Muc1 whole-body knockout rats and / or injecting tamoxifen into abdominal cavities of the mice when the Muc1 type II alveolar epithelial cell knockout mice are 6-8 weeks old, and then exposing tobacco smoke every one week. According to the invention, a series of evaluations are carried out on lung tissue pathological changes, lung epithelial cell changes and other indexes of the constructed model product, and the success of the construction of the chronic obstructive pulmonary pulmonary epithelial cell senescence model is jointly proved.

MUC1 is overexpressed in many cancers, including those of the lung, colon, breast, ovary, and pancreas. Aspects of the invention are directed towards the discovery of monoclonal antibodies and fragments thereof, such as a human single chain variable fragment (scFv), that recognizes human MUC1-SEA.

This disclosure relates to binding domains and binding moieties, for example, in the field of antibodies. More specifically, this disclosure relates to the field of therapeutic antibodies for the treatment of cancer. More specifically, this disclosure relates to binding domains that bind to cancer-related MUC1, and binding moieties that include such binding domains. [Solution] This disclosure relates to binding domains that bind to cancer-associated MUC1, and binding moieties comprising such binding domains. This disclosure further relates to the use of such binding domains or binding moieties in the treatment of cancer. This disclosure also relates to nucleic acids encoding such binding domains or binding moieties, and vectors and cells comprising such nucleic acids.